NRX Pharmaceuticals (NASDAQ:NRXP) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $0.06 by 833.33 percent. This is a 55.1 percent increase over losses of $(0.98) per share from the same period last year. The company reported quarterly sales of $1.101 million which missed the analyst consensus estimate of $17.488 million by 93.70 percent.